Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Richard C TurkingtonLaura A KnightJaine K BlayneyMaria SecrierRosalie DouglasEileen E ParkesEilis K SuttonLeanne StevensonDamian McManusSophia HallidayAndrena M McCaviganGemma E LoganSteven M WalkerChristopher J SteeleJuliane PernerJan BornscheinShona MacRaeAhmad MiremadiEamon McCarronStephen McQuaidKenneth ArthurJacqueline A JamesMartin M EatockRobert O'NeillFergus NobleTimothy J UnderwoodD Paul HarkinManuel Salto-TellezRebecca C FitzgeraldRichard D Kennedynull nullPublished in: Gut (2019)
The DDIR assay is strongly predictive of benefit from DNA-damaging neoadjuvant chemotherapy followed by surgical resection and is associated with a proinflammatory microenvironment in OAC.